FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2587016783> ?p ?o ?g. }

• W2587016783 endingPage "S385" @default.
• W2587016783 startingPage "S384" @default.
• W2587016783 abstract "Background: Efficacy of ustekinumab (UST) in Crohn's disease (CD) has been demonstrated in clinical trials. Real world symptomatic and endoscopic response is lacking. As opposed to intravenous (IV) induction, high dose subcutaneous (SC) induction has been proposed while the IV formulation is unavailable. Methods: A retrospective, observational study of 2 different induction regimens was conducted. Standard dosing was 90mg SC at Week 0, 1 and 2; higher dose induction 270mg SC at Week 0 and 180mg SC at Weeks 1 and 2. Maintenance dosing was 90mg SC every 8 weeks for both induction regimens. Response assessed after 3 months (short term), and if remaining on therapy, after 6–12 months (medium term) and at least 12 months (long term). Symptomatic response defined as physician documentation of improvement of CD-associated symptoms, withdrawal of steroids and continuation of therapy. Endoscopic or radiological response defined as resolution or improvement in extent and severity of lesions. Results: Seventy-nine patients commenced UST for CD from September 2012 to November 2016.(Figure 1) Five patients were lost to follow-up, with 74 patients remaining, including 39 induced with higher dose (Table 1). Maintenance dose escalation occurred in 17 patients (90mg every 4 weeks), of whom 13 and 4 had received standard and high induction. Symptomatic response assessed in 66 patients; 51% (17/33) in standard and 67% (22/33) in higher induction groups had short term symptomatic response. Biochemical response was seen in 64% (9/14) and 58% (11/19) of patients in standard and higher induction groups. Within the first 3 months, 29% (10/35) of standard and 8% (3/36) of higher induction groups ceased therapy. Symptomatic response was reported in 68% (15/22) of standard and 57% (13/23) of higher induction groups who continued on UST in medium term; in long term, 64% (14/22) and 80% (4/5) have an ongoing response. Endoscopic or radiologic response or improvement was achieved in 50% (10/20) and 71% (12/17) of standard and high induction groups. Of primary and secondary anti-TNF non-responders, 88% (14/16) and 56% (18/32) had short term symptomatic response. Conclusions: Fifty-nine percent of patients had short term symptomatic response, with greater proportion receiving higher induction strategy, while primary non-response to prior anti-TNF was also associated with response. Fewer patients receiving high dose induction required dose escalation. Endoscopic or radiologic assessment also demonstrated greater improvement or response within this novel induction group. Results provide further encouragement for therapeutic benefit of UST in CD." @default.
• W2587016783 created "2017-02-17" @default.
• W2587016783 creator A5041382997 @default.
• W2587016783 creator A5051888041 @default.
• W2587016783 creator A5062818239 @default.
• W2587016783 date "2017-01-26" @default.
• W2587016783 modified "2023-10-18" @default.
• W2587016783 title "P597 Ustekinumab use in Crohn's disease: a tertiary centre experience" @default.
• W2587016783 doi "https://doi.org/10.1093/ecco-jcc/jjx002.721" @default.
• W2587016783 hasPublicationYear "2017" @default.
• W2587016783 type Work @default.
• W2587016783 sameAs 2587016783 @default.
• W2587016783 citedByCount "2" @default.
• W2587016783 countsByYear W25870167832020 @default.
• W2587016783 crossrefType "journal-article" @default.
• W2587016783 hasAuthorship W2587016783A5041382997 @default.
• W2587016783 hasAuthorship W2587016783A5051888041 @default.
• W2587016783 hasAuthorship W2587016783A5062818239 @default.
• W2587016783 hasBestOaLocation W25870167831 @default.
• W2587016783 hasConcept C126322002 @default.
• W2587016783 hasConcept C141071460 @default.
• W2587016783 hasConcept C167135981 @default.
• W2587016783 hasConcept C190892606 @default.
• W2587016783 hasConcept C23131810 @default.
• W2587016783 hasConcept C2776611710 @default.
• W2587016783 hasConcept C2776694085 @default.
• W2587016783 hasConcept C2777138892 @default.
• W2587016783 hasConcept C2777288759 @default.
• W2587016783 hasConcept C2778283404 @default.
• W2587016783 hasConcept C2778975655 @default.
• W2587016783 hasConcept C2779134260 @default.
• W2587016783 hasConcept C2779280984 @default.
• W2587016783 hasConcept C2991767035 @default.
• W2587016783 hasConcept C3019096185 @default.
• W2587016783 hasConcept C71924100 @default.
• W2587016783 hasConcept C90924648 @default.
• W2587016783 hasConceptScore W2587016783C126322002 @default.
• W2587016783 hasConceptScore W2587016783C141071460 @default.
• W2587016783 hasConceptScore W2587016783C167135981 @default.
• W2587016783 hasConceptScore W2587016783C190892606 @default.
• W2587016783 hasConceptScore W2587016783C23131810 @default.
• W2587016783 hasConceptScore W2587016783C2776611710 @default.
• W2587016783 hasConceptScore W2587016783C2776694085 @default.
• W2587016783 hasConceptScore W2587016783C2777138892 @default.
• W2587016783 hasConceptScore W2587016783C2777288759 @default.
• W2587016783 hasConceptScore W2587016783C2778283404 @default.
• W2587016783 hasConceptScore W2587016783C2778975655 @default.
• W2587016783 hasConceptScore W2587016783C2779134260 @default.
• W2587016783 hasConceptScore W2587016783C2779280984 @default.
• W2587016783 hasConceptScore W2587016783C2991767035 @default.
• W2587016783 hasConceptScore W2587016783C3019096185 @default.
• W2587016783 hasConceptScore W2587016783C71924100 @default.
• W2587016783 hasConceptScore W2587016783C90924648 @default.
• W2587016783 hasIssue "suppl_1" @default.
• W2587016783 hasLocation W25870167831 @default.
• W2587016783 hasOpenAccess W2587016783 @default.
• W2587016783 hasPrimaryLocation W25870167831 @default.
• W2587016783 hasRelatedWork W1995820326 @default.
• W2587016783 hasRelatedWork W2466082667 @default.
• W2587016783 hasRelatedWork W2589322081 @default.
• W2587016783 hasRelatedWork W2912485652 @default.
• W2587016783 hasRelatedWork W2977414899 @default.
• W2587016783 hasRelatedWork W3180072626 @default.
• W2587016783 hasRelatedWork W3191351618 @default.
• W2587016783 hasRelatedWork W4254732745 @default.
• W2587016783 hasRelatedWork W4318539897 @default.
• W2587016783 hasRelatedWork W4360601350 @default.
• W2587016783 hasVolume "11" @default.
• W2587016783 isParatext "false" @default.
• W2587016783 isRetracted "false" @default.
• W2587016783 magId "2587016783" @default.
• W2587016783 workType "article" @default.